Leo Edward Gerweck, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Tolerance | 15 | 2024 | 486 | 1.510 |
Why?
|
| Neoplasms, Experimental | 12 | 2014 | 1276 | 1.140 |
Why?
|
| Hydrogen-Ion Concentration | 27 | 2012 | 2557 | 1.120 |
Why?
|
| Hot Temperature | 29 | 2012 | 1354 | 0.960 |
Why?
|
| Cell Survival | 33 | 2024 | 5882 | 0.860 |
Why?
|
| Oxygen | 16 | 2023 | 4189 | 0.700 |
Why?
|
| Radiotherapy Dosage | 11 | 2023 | 2879 | 0.560 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2014 | 117 | 0.560 |
Why?
|
| Chlorambucil | 3 | 2006 | 43 | 0.520 |
Why?
|
| Radiosurgery | 1 | 2024 | 1329 | 0.480 |
Why?
|
| Whole-Body Irradiation | 2 | 2014 | 449 | 0.480 |
Why?
|
| Neutrons | 1 | 2014 | 76 | 0.480 |
Why?
|
| Neoplasms | 16 | 2023 | 21683 | 0.460 |
Why?
|
| Cricetinae | 31 | 2015 | 2472 | 0.440 |
Why?
|
| Fibrosarcoma | 8 | 2003 | 348 | 0.430 |
Why?
|
| Scattering, Radiation | 1 | 2014 | 498 | 0.420 |
Why?
|
| Cell Hypoxia | 7 | 2003 | 675 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2014 | 547 | 0.360 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 594 | 0.360 |
Why?
|
| Radiobiology | 3 | 2023 | 85 | 0.350 |
Why?
|
| Dose-Response Relationship, Radiation | 10 | 2024 | 876 | 0.340 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 1376 | 0.320 |
Why?
|
| Cricetulus | 20 | 2015 | 816 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 13 | 2021 | 6314 | 0.310 |
Why?
|
| Energy Metabolism | 11 | 1995 | 2899 | 0.300 |
Why?
|
| Mice, Nude | 11 | 2017 | 3689 | 0.280 |
Why?
|
| Doxorubicin | 2 | 2006 | 2234 | 0.280 |
Why?
|
| Longevity | 1 | 2014 | 1070 | 0.280 |
Why?
|
| Temperature | 2 | 2012 | 2206 | 0.270 |
Why?
|
| Hyperthermia, Induced | 6 | 1990 | 403 | 0.260 |
Why?
|
| Relative Biological Effectiveness | 4 | 2010 | 323 | 0.260 |
Why?
|
| Neoplasm Transplantation | 9 | 2014 | 2085 | 0.250 |
Why?
|
| Extracellular Space | 5 | 2006 | 594 | 0.240 |
Why?
|
| Adaptation, Physiological | 5 | 1998 | 1312 | 0.240 |
Why?
|
| Ovary | 19 | 1990 | 981 | 0.230 |
Why?
|
| Protons | 4 | 2023 | 1127 | 0.220 |
Why?
|
| Animals | 71 | 2023 | 168757 | 0.200 |
Why?
|
| Mice, Inbred C3H | 10 | 2003 | 964 | 0.190 |
Why?
|
| Mice, SCID | 3 | 2014 | 2716 | 0.180 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2021 | 520 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2001 | 627 | 0.180 |
Why?
|
| Losartan | 1 | 2021 | 299 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 420 | 0.170 |
Why?
|
| Cell Membrane | 6 | 2001 | 3748 | 0.170 |
Why?
|
| CHO Cells | 4 | 1999 | 1406 | 0.160 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2015 | 228 | 0.160 |
Why?
|
| Radiation Dosage | 4 | 2024 | 1928 | 0.160 |
Why?
|
| Glucose | 6 | 2006 | 4397 | 0.160 |
Why?
|
| Antineoplastic Agents | 6 | 2006 | 13695 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 451 | 0.150 |
Why?
|
| Isotretinoin | 1 | 1998 | 114 | 0.150 |
Why?
|
| Mice | 32 | 2023 | 81183 | 0.140 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1998 | 358 | 0.140 |
Why?
|
| Lens, Crystalline | 2 | 2018 | 388 | 0.140 |
Why?
|
| Stromal Cells | 2 | 2014 | 1355 | 0.130 |
Why?
|
| Cell Line | 23 | 2015 | 15997 | 0.130 |
Why?
|
| Lethal Dose 50 | 1 | 2014 | 77 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 1995 | 121 | 0.130 |
Why?
|
| Glioblastoma | 6 | 2017 | 3481 | 0.120 |
Why?
|
| Acclimatization | 3 | 1984 | 103 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2018 | 419 | 0.120 |
Why?
|
| Intracellular Fluid | 2 | 1999 | 203 | 0.120 |
Why?
|
| Phosphocreatine | 6 | 1995 | 269 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 1998 | 895 | 0.120 |
Why?
|
| Transfection | 4 | 2014 | 5892 | 0.120 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 1254 | 0.120 |
Why?
|
| Drug Design | 1 | 1998 | 1076 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 1998 | 3760 | 0.110 |
Why?
|
| Cell Death | 1 | 1998 | 1706 | 0.110 |
Why?
|
| Cells, Cultured | 16 | 2012 | 19229 | 0.110 |
Why?
|
| DNA Repair | 4 | 2010 | 2046 | 0.090 |
Why?
|
| Androgens | 1 | 1997 | 1281 | 0.080 |
Why?
|
| Cysteamine | 3 | 1985 | 23 | 0.080 |
Why?
|
| DNA Damage | 3 | 2010 | 2432 | 0.080 |
Why?
|
| Adenosine Triphosphate | 6 | 1993 | 2025 | 0.080 |
Why?
|
| Apoptosis | 2 | 2015 | 9727 | 0.080 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 1827 | 0.080 |
Why?
|
| Sarcoma, Experimental | 4 | 1995 | 128 | 0.080 |
Why?
|
| Body Fluids | 1 | 1988 | 319 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 13102 | 0.070 |
Why?
|
| Bone Transplantation | 3 | 1997 | 907 | 0.070 |
Why?
|
| Linear Energy Transfer | 2 | 2010 | 154 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 399 | 0.070 |
Why?
|
| Indazoles | 1 | 1988 | 289 | 0.070 |
Why?
|
| Carbon | 1 | 2010 | 687 | 0.070 |
Why?
|
| Humans | 38 | 2024 | 744343 | 0.070 |
Why?
|
| Muscles | 1 | 1991 | 1614 | 0.070 |
Why?
|
| Restriction Mapping | 1 | 2006 | 878 | 0.070 |
Why?
|
| Catalase | 2 | 1984 | 222 | 0.060 |
Why?
|
| Extremities | 1 | 1990 | 865 | 0.060 |
Why?
|
| Oxygen Consumption | 3 | 1988 | 1869 | 0.060 |
Why?
|
| Cell Division | 4 | 1986 | 4568 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 16689 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 3 | 1997 | 1351 | 0.060 |
Why?
|
| Propionibacterium acnes | 1 | 1984 | 66 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2012 | 2740 | 0.060 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2006 | 223 | 0.060 |
Why?
|
| Misonidazole | 1 | 2003 | 34 | 0.060 |
Why?
|
| Cisplatin | 1 | 1990 | 1662 | 0.060 |
Why?
|
| Glioma | 4 | 2008 | 3401 | 0.060 |
Why?
|
| Kinetics | 5 | 1999 | 6473 | 0.060 |
Why?
|
| Phosphorus | 2 | 1998 | 338 | 0.060 |
Why?
|
| Monosaccharides | 1 | 2003 | 70 | 0.060 |
Why?
|
| Cause of Death | 1 | 2014 | 3584 | 0.060 |
Why?
|
| Bone Development | 3 | 1997 | 483 | 0.060 |
Why?
|
| Nitroimidazoles | 1 | 2003 | 106 | 0.050 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 8863 | 0.050 |
Why?
|
| Superoxide Dismutase | 2 | 1984 | 597 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2003 | 137 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1758 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2017 | 3752 | 0.050 |
Why?
|
| Cell Physiological Phenomena | 1 | 1982 | 154 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 8949 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 1363 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 1144 | 0.050 |
Why?
|
| Phosphates | 3 | 1995 | 786 | 0.050 |
Why?
|
| Adenosine Diphosphate | 2 | 1993 | 425 | 0.050 |
Why?
|
| Time Factors | 16 | 1998 | 40075 | 0.040 |
Why?
|
| X-Rays | 6 | 2000 | 301 | 0.040 |
Why?
|
| Radiation Effects | 2 | 1975 | 68 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2008 | 2132 | 0.040 |
Why?
|
| Sarcoma | 1 | 1990 | 1897 | 0.040 |
Why?
|
| Photons | 1 | 2023 | 588 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1995 | 4034 | 0.040 |
Why?
|
| Alkalies | 1 | 1998 | 52 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2003 | 2327 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 1998 | 152 | 0.040 |
Why?
|
| Aerobiosis | 2 | 1992 | 106 | 0.040 |
Why?
|
| Acids | 1 | 1998 | 127 | 0.040 |
Why?
|
| Female | 30 | 2021 | 380194 | 0.040 |
Why?
|
| Pyrazoles | 1 | 1988 | 1972 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 2 | 1995 | 117 | 0.040 |
Why?
|
| Age Factors | 1 | 2014 | 18370 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 1792 | 0.040 |
Why?
|
| Lung | 3 | 2015 | 9856 | 0.040 |
Why?
|
| Solubility | 1 | 1998 | 1085 | 0.040 |
Why?
|
| Diffusion | 1 | 1998 | 833 | 0.030 |
Why?
|
| Freezing | 1 | 1996 | 303 | 0.030 |
Why?
|
| Heating | 1 | 1996 | 97 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 2635 | 0.030 |
Why?
|
| Partial Pressure | 1 | 1995 | 254 | 0.030 |
Why?
|
| Combined Modality Therapy | 4 | 1998 | 8642 | 0.030 |
Why?
|
| Neuroglia | 1 | 1980 | 927 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1995 | 155 | 0.030 |
Why?
|
| Brain | 3 | 2018 | 26385 | 0.030 |
Why?
|
| Microelectrodes | 1 | 1996 | 303 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20129 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 546 | 0.030 |
Why?
|
| Ribonucleotides | 1 | 1995 | 117 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1997 | 599 | 0.030 |
Why?
|
| Orchiectomy | 1 | 1997 | 474 | 0.030 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1995 | 163 | 0.030 |
Why?
|
| Indomethacin | 1 | 1995 | 332 | 0.030 |
Why?
|
| Biological Transport | 1 | 1999 | 2118 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 3557 | 0.030 |
Why?
|
| Head | 1 | 2018 | 880 | 0.030 |
Why?
|
| Crystallins | 1 | 1972 | 75 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1996 | 981 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1994 | 755 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 5853 | 0.030 |
Why?
|
| Tritium | 1 | 1972 | 745 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 6622 | 0.020 |
Why?
|
| Weights and Measures | 1 | 1991 | 43 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 2416 | 0.020 |
Why?
|
| Proteins | 1 | 1986 | 6103 | 0.020 |
Why?
|
| Rats | 5 | 1994 | 24260 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1991 | 425 | 0.020 |
Why?
|
| Fast Neutrons | 1 | 2010 | 18 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15076 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 19905 | 0.020 |
Why?
|
| Nucleotides | 2 | 1990 | 464 | 0.020 |
Why?
|
| Cell Cycle | 2 | 1995 | 2967 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 2480 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 9648 | 0.020 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1990 | 197 | 0.020 |
Why?
|
| Male | 11 | 2017 | 350118 | 0.020 |
Why?
|
| Skin | 1 | 2023 | 4364 | 0.020 |
Why?
|
| Mathematics | 2 | 1983 | 728 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 1995 | 2382 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1991 | 694 | 0.020 |
Why?
|
| Neurilemmoma | 1 | 1994 | 547 | 0.020 |
Why?
|
| Thermodynamics | 1 | 1990 | 596 | 0.020 |
Why?
|
| Immunotherapy | 1 | 1984 | 4445 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1990 | 431 | 0.020 |
Why?
|
| Mannitol | 1 | 1988 | 181 | 0.020 |
Why?
|
| Organ Specificity | 2 | 2003 | 2008 | 0.020 |
Why?
|
| Ion Channels | 1 | 1993 | 1056 | 0.020 |
Why?
|
| Culture Media | 3 | 1995 | 908 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 170 | 0.020 |
Why?
|
| Lipids | 1 | 1998 | 3305 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1993 | 1609 | 0.020 |
Why?
|
| Adenosine Monophosphate | 1 | 1988 | 275 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12788 | 0.020 |
Why?
|
| Methods | 2 | 1994 | 1129 | 0.020 |
Why?
|
| Skin Window Technique | 2 | 1996 | 22 | 0.020 |
Why?
|
| Glutathione | 2 | 1985 | 589 | 0.020 |
Why?
|
| Testosterone | 1 | 1997 | 2420 | 0.020 |
Why?
|
| Culture Techniques | 2 | 1997 | 554 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 689 | 0.020 |
Why?
|
| Probability | 1 | 1990 | 2505 | 0.020 |
Why?
|
| Remission Induction | 1 | 1990 | 2386 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 2282 | 0.020 |
Why?
|
| Femur | 3 | 1996 | 1297 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1988 | 10943 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1984 | 90 | 0.020 |
Why?
|
| Regional Blood Flow | 2 | 1997 | 1525 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1985 | 298 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1994 | 2575 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 1813 | 0.010 |
Why?
|
| Protein Denaturation | 2 | 1988 | 237 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 380 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 21827 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2002 | 118 | 0.010 |
Why?
|
| Histamine | 1 | 1984 | 507 | 0.010 |
Why?
|
| Anaerobiosis | 1 | 1982 | 140 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 1986 | 822 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10481 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 3768 | 0.010 |
Why?
|
| Glycolysis | 1 | 1985 | 827 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1538 | 0.010 |
Why?
|
| Radium | 1 | 1981 | 65 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1994 | 12245 | 0.010 |
Why?
|
| Animals, Newborn | 2 | 1996 | 2726 | 0.010 |
Why?
|
| Rabbits | 2 | 1979 | 4894 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 2 | 1994 | 257 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 2421 | 0.010 |
Why?
|
| X-Ray Therapy | 1 | 1977 | 9 | 0.010 |
Why?
|
| Electrons | 1 | 1979 | 268 | 0.010 |
Why?
|
| Rectum | 1 | 2002 | 904 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 326 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1982 | 3128 | 0.010 |
Why?
|
| Blood Physiological Phenomena | 1 | 1995 | 55 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 4982 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1995 | 175 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1995 | 226 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1180 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 63114 | 0.010 |
Why?
|
| Body Temperature | 1 | 1977 | 777 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1994 | 249 | 0.010 |
Why?
|
| Cartilage | 1 | 1997 | 818 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 14557 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1995 | 813 | 0.010 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1977 | 736 | 0.010 |
Why?
|
| Histidine | 1 | 1972 | 313 | 0.010 |
Why?
|
| Mitosis | 1 | 1975 | 1208 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1990 | 244 | 0.010 |
Why?
|
| Oxidation-Reduction | 2 | 1985 | 2187 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1994 | 670 | 0.010 |
Why?
|
| Macrophages | 1 | 1984 | 5655 | 0.010 |
Why?
|
| Models, Biological | 2 | 2000 | 9583 | 0.010 |
Why?
|
| Cattle | 1 | 1995 | 3922 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1994 | 1701 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1995 | 1318 | 0.000 |
Why?
|
| Radiometry | 1 | 1972 | 800 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1997 | 2948 | 0.000 |
Why?
|
| Ditiocarb | 1 | 1984 | 5 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1984 | 101 | 0.000 |
Why?
|
| Cell Movement | 1 | 1977 | 5217 | 0.000 |
Why?
|
| Pentetic Acid | 1 | 1984 | 213 | 0.000 |
Why?
|
| Peroxides | 1 | 1984 | 74 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1984 | 276 | 0.000 |
Why?
|
| Antibodies | 1 | 1993 | 2460 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 3772 | 0.000 |
Why?
|
| Microcirculation | 1 | 1988 | 1286 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 8301 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1988 | 1533 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1980 | 5686 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13815 | 0.000 |
Why?
|
| Peptides | 1 | 1993 | 4409 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1988 | 4011 | 0.000 |
Why?
|
| Cysteine | 1 | 1984 | 874 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 18111 | 0.000 |
Why?
|
| Cytological Techniques | 1 | 1981 | 219 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11124 | 0.000 |
Why?
|
| Ischemia | 1 | 1986 | 1907 | 0.000 |
Why?
|
| Middle Aged | 1 | 1990 | 213383 | 0.000 |
Why?
|
| Brachytherapy | 1 | 1981 | 1248 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 7913 | 0.000 |
Why?
|
| Research Design | 1 | 1988 | 5987 | 0.000 |
Why?
|
| Mutation | 1 | 1994 | 29786 | 0.000 |
Why?
|